Clinical Trials Browser

Recurrence × camrelizumab × Lymphoid × Clear all

NCT05320081 2022-04-11

Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma

Phase 2 Unknown

Lymphoma, Recurrence

NCT04476459 2021-03-15

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

Phase 1/2 Unknown

Recurrence, Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT03250962 2019-04-01

SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Unknown

Hodgkin Disease, Recurrence